Pediatric Growth Hormone Deficiency (PGHD) Market to Observe Impressive Growth by 2032 | Key Companies – Pfizer, Opko Health, Novo Nordisk, Ascendis Pharma, Lumos Pharma, and Others

Delveinsight Business Research LLP
DelveInsight’s “Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Pediatric Growth Hormone Deficiency Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Pediatric Growth Hormone Deficiency market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market. 

Pediatric Growth Hormone Deficiency: An Overview

Pediatric Growth Hormone Deficiency (PGHD) occurs when the pituitary gland does not make enough growth hormone. It can be caused by damage to the pituitary gland or another gland called the hypothalamus. The injury can occur before birth (congenital), or during or after birth (acquired).

The child is more at risk for GH deficiency if they have any of these like brain injury, brain tumor, radiation treatment to the head. To diagnose the GH deficiency, the healthcare providers need to check for conditions such as normal variations of growth, such as familial short stature; other disorders, such as thyroid hormone deficiency or kidney disease, and genetic conditions. The tests like blood tests, X-rays, CT scans, and MRI.

Treatment is mainly done with daily injections of synthetic growth hormone, results are often seen as soon as 3-4 months after treatment starts. The treatment can last several years until late puberty when growing is finished.

Pediatric Growth Hormone Deficiency Market Key Facts

As per the study by Bonfig Walter et al. the Growth Hormone Deficiency prevalence ranges between 1:3500 and 1:8700 in Germany.

According to Boston’s Children’s Hospital, about one in 4,000 to 10,000 children have a growth hormone deficiency.

According to Brod Meryl et al., the prevalence of childhood Growth Hormone Deficiency reported in published studies is within the range of 1.8–2.9 per 10,000 in Europe.

According to the NORD, Growth hormone deficiency affects males and females equally. However, given the greater concern for boys with short stature in most societies, diagnosis tends to favor males over females. About 73% of patients with idiopathic GHD in the NCGS were male. Additionally, patients with GHD from organic causes such as tumors and radiation, in which no gender bias should be present, were still 62% male.

Pediatric Growth Hormone Deficiency Market

Pediatric Growth Hormone Deficiency (PGHD) Market Size is anticipated to increase in the coming years owing to the increasing prevalent population and expected entry of long-acting hGH emerging therapies for PGHD treatment in the 7MM.

Of the emerging therapies, the most anticipated product to get launched in the market includes TransCon hGH, Somapacitan, Somatrogon, LUM-201, and others. These therapies are expected to change the Growth Hormone Deficiency market dynamics in the upcoming years. Some of the Growth Hormone Deficiency therapies also got Orphan designation.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Pediatric Growth Hormone Deficiency market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Pediatric Growth Hormone Deficiency market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Pediatric Growth Hormone Deficiency Epidemiology

The epidemiology section covers insights into the historical and current Pediatric Growth Hormone Deficiency patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Pediatric Growth Hormone Deficiency (PGHD) Epidemiology Segmentation

Total Prevalent Pool of GHD

Total Prevalent Patient Pool of PGHD

Diagnosed Patient Pool of PGHD

Treated Patient Pool of PGHD

Pediatric Growth Hormone Deficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pediatric Growth Hormone Deficiency market or expected to get launched in the market during the study period. The analysis covers Pediatric Growth Hormone Deficiency market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Pediatric Growth Hormone Deficiency Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Pediatric Growth Hormone Deficiency Therapeutics Analysis

The available therapeutic treatment options in the Pediatric Growth Hormone Deficiency (PGHD) landscape aims for long-term efficacy. As per DelveInsight, Pediatric Growth Hormone Deficiency (PGHD) market dynamics is anticipated to change in the coming years owing to the improvement in healthcare spending across the world.

Some of the key Companies in the Pediatric Growth Hormone Deficiency (PGHD) Market include:


Opko health

Novo Nordisk

Ascendis Pharma

Lumos Pharma

And others

Pediatric Growth Hormone Deficiency (PGHD) Therapies covered in the report include:


TransCon hGH



And many more. 

The pipeline for Pediatric Growth Hormone Deficiency (PGHD) is full of long-acting hGH as it is the major unmet need of this indication. On the other hand, the current pipeline is robust with late-stage products and will change the dynamics of the upcoming market. 

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Pediatric Growth Hormone Deficiency Competitive Intelligence Analysis

4. Pediatric Growth Hormone Deficiency Market Overview at a Glance

5. Pediatric Growth Hormone Deficiency Disease Background and Overview

6. Pediatric Growth Hormone Deficiency Patient Journey

7. Pediatric Growth Hormone Deficiency Epidemiology and Patient Population

8. Pediatric Growth Hormone Deficiency Treatment Algorithm, Current Treatment, and Medical Practices

9. Pediatric Growth Hormone Deficiency Unmet Needs

10. Key Endpoints of Pediatric Growth Hormone Deficiency Treatment

11. Pediatric Growth Hormone Deficiency Marketed Products

12. Pediatric Growth Hormone Deficiency Emerging Therapies

13. Pediatric Growth Hormone Deficiency Seven Major Market Analysis

14. Attribute Analysis

15. Pediatric Growth Hormone Deficiency Market Outlook (7 major markets)

16. Pediatric Growth Hormone Deficiency Access and Reimbursement Overview

17. KOL Views on the Pediatric Growth Hormone Deficiency Market.

18. Pediatric Growth Hormone Deficiency Market Drivers

19. Pediatric Growth Hormone Deficiency Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

Latest Reports By DelveInsight

Bevacizumab Biosimilars Insight

DelveInsight’s, “Bevacizumab Biosimilar Insight” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. The report also covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States